Clinical trialNCT06971939RecruitingPhase 4Interventional

Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

SponsorNeurotech PharmaceuticalsEnrollment234Macular Telangiectasia Type 2 (MacTel)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501), in participants with macular telangiectasia type 2 (MacTel) who previously received the intraocular implant in a Phase 1, Phase 2, or Phase 3 clinical study and have retained at least 1 NT-501 at study entry. In addition, this study will evaluate the safety and efficacy of NT501 in participants who previously underwent the sham procedure in a Phase 3 MacTel clinical study and elect to have NT-501 implanted intraocularly in this Phase 4 study.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Thomas Aaberg, Jr, MD
Neurotech Pharmaceuticals
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Cerulea
East Melbourne, Australia
Penelope Allen, MD
Recruiting
Lion'S Eye Institute
Perth, Australia
Ian Constable, MD
Recruiting
Sydney Eye Hospital
Sydney, Australia
Elisa Cornish, MD
Recruiting

United States

Scripps Health
La Jolla, California, United States
Richard Lin, MD
Not, yet, recruiting
Jules Stein Eye Institute/ucla
Los Angeles, California, United States
Colin McCannel, MD
Not, yet, recruiting
Stanford University School of Medicine
Palo Alto, California, United States
Diana Do, MD
Not, yet, recruiting
Bay Area Retina Associates
Walnut Creek, California, United States
Roger Goldberg, MD
Recruiting
Colorado Retina
Lakewood, Colorado, United States
Murtaza Adam, MD
Not, yet, recruiting
Bascom Palmer
Miami, Florida, United States
Philip Rosenfield, MD
Not, yet, recruiting
Emory Eye Center
Atlanta, Georgia, United States
Jiong Yan, MD
Recruiting
Northwestern University
Chicago, Illinois, United States
Ivy Zhu, MD
Recruiting
National Eye Institute
Bethesda, Maryland, United States
Tiarnan Keenan, MD
Not, yet, recruiting
Cumberland Valley Retina Consultants
Frederick, Maryland, United States
David Warrow, MD
Not, yet, recruiting
Massachusetts Eye and Ear Infirmary, Retina Service
Boston, Massachusetts, United States
Dean Eliott, MD
Not, yet, recruiting
Foundation for Vision Research
Grand Rapids, Michigan, United States
Liliya Sutherland, MD
Recruiting
Retina Consultants of Minnesota
Minneapolis, Minnesota, United States
Abdhish Bhavsar, MD
Not, yet, recruiting
Envision Ocular, Llc
Bloomfield, New Jersey, United States
Patrick Higgins, MD
Not, yet, recruiting
Cincinnati Eye Institute
Cincinnati, Ohio, United States
Lucas Lindsell, MD
Recruiting
Retina Associates of Cleveland, Inc.
Cleveland, Ohio, United States
Joseph Coney, MD
Recruiting
Retina Northwest, P.C.
Portland, Oregon, United States
Michael Lee, MD
Not, yet, recruiting
Scheie Eye Institute
Philadelphia, Pennsylvania, United States
Alexander Brucker, MD
Not, yet, recruiting
Southeastern Retina Associates, P.C.
Knoxville, Tennessee, United States
Stephen Perkins, MD
Recruiting
Retina Center of Texas
Dallas, Texas, United States
Jawad Qureshi, MD
Recruiting
Texas Retina Associates
Dallas, Texas, United States
Ashkan Abbey, MD
Recruiting
Retina Consultants of Texas
Houston, Texas, United States
Charles Wykoff, MD
Recruiting
University of Utah John A. Moran Center
Salt Lake City, Utah, United States
Paul Bernstein, MD
Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Nov 2025
Primary completion: 15 Jan 2032
Completion: 15 Jan 2032
Last update posted: 13 Aug 2026
Registered enrollment: 234
Registry id: NCT06971939

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.